For the Inventor, By the Inventor

Enter assignee name

Foster City, CA, United States of America

Gilead Connecticut, Inc.

USPTO Granted Patents = 30

CIPO Patents = 9

EPO Patents = 16

Forward Citations = 443

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Scott A Mitchell (23 out of 67 patents)

Kevin S Currie (22 out of 72 patents)

Peter A Blomgren (18 out of 53 patents)

4. Jeffrey E Kropf (16 out of 45 patents)

5. Jianjun Xu (16 out of 40 patents)

6. Seung H Lee (15 out of 37 patents)

7. Zhongdong Zhao (11 out of 32 patents)

8. Aaron C Schmitt (9 out of 25 patents)

9. Douglas Gregory Stafford (8 out of 15 patents)

10. Pavel E Zhichkin (7 out of 14 patents)

11. Wendy B Young (7 out of 30 patents)

12. Xiaojing Wang (6 out of 34 patents)

13. Daniel Fred Ortwine (5 out of 31 patents)

14. Antonio J M Barbosa (5 out of 6 patents)

15. Dimitrios Stefanidis (5 out of 29 patents)

30 patents: Sort by Forward Citations

1. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

2. 10266539 - Polymorph of Syk inhibitors (2019-04-23),

3. 10093684 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2018-10-09),

4. 10092583 - Imidazopyridines Syk inhibitors (2018-10-09),

5. 10053469 - Pyridone and aza-pyridone compounds and methods of use (2018-08-21),

6. 9949932 - Formulation of syk inhibitors (2018-04-24),

7. 9918939 - Formulation of Syk inhibitors (2018-03-20),

8. 9796718 - 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine (2017-10-24),

9. 9657023 - Polymorph of Syk inhibitors (2017-05-23),

10. 9567348 - Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors (2017-02-14),

11. 9562056 - Imidazopyridines Syk inhibitors (2017-02-07),

12. 9505785 - Pyridone and aza-pyridone compounds and methods of use (2016-11-29),

13. 9382256 - Formulation of Syk inhibitors (2016-07-05),

14. 9249123 - Pyridinones/pyrazinones, method of making, and method of use thereof (2016-02-02),

15. 9212191 - 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor (2015-12-15),

Gilead Connecticut, Inc. is a leading biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines. With a mission to improve the lives of individuals suffering from serious illnesses, Gilead Connecticut, Inc. strives to discover and develop breakthrough treatments for diseases such as HIV/AIDS, viral hepatitis, oncology, and more.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

30 Patents

#17 in Foster City, CA

#2,592 in California

#10,873 in US

#21,209 in the World

Foster City, CA, United States of America

Gilead Connecticut, Inc.

Forward Citations = 443

36 inventors:

Scott A Mitchell (23 out of 67 patents)

Kevin S Currie (22 out of 72 patents)

Peter A Blomgren (18 out of 53 patents)

4. Jeffrey E Kropf (16 out of 45 patents)

5. Jianjun Xu (16 out of 40 patents)

Please report any incorrect information to support@idiyas.com

Loading…